Insider Selling: Arvinas Inc (NASDAQ:ARVN) Insider Sells $280,000.00 in Stock

Arvinas Inc (NASDAQ:ARVN) insider Ian Taylor sold 10,000 shares of Arvinas stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $28.00, for a total value of $280,000.00. Following the sale, the insider now owns 55,496 shares of the company’s stock, valued at approximately $1,553,888. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Ian Taylor also recently made the following trade(s):

  • On Monday, September 30th, Ian Taylor sold 10,000 shares of Arvinas stock. The stock was sold at an average price of $21.86, for a total value of $218,600.00.

Arvinas stock opened at $30.49 on Monday. The stock has a market cap of $1.01 billion, a PE ratio of -1.20 and a beta of 2.13. The stock has a 50-day moving average price of $20.72 and a 200 day moving average price of $22.66. Arvinas Inc has a 52 week low of $10.19 and a 52 week high of $30.85. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.03.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.67. The firm had revenue of $30.05 million during the quarter, compared to analysts’ expectations of $11.42 million. Arvinas had a negative return on equity of 31.57% and a negative net margin of 157.34%. On average, equities analysts predict that Arvinas Inc will post -1.94 EPS for the current year.

A number of analysts recently commented on ARVN shares. Cantor Fitzgerald started coverage on Arvinas in a research report on Monday, August 5th. They set an “overweight” rating and a $42.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and set a $35.00 price objective (up previously from $32.00) on shares of Arvinas in a research report on Wednesday, November 13th. BMO Capital Markets started coverage on Arvinas in a research report on Thursday, September 12th. They set an “outperform” rating and a $34.00 price objective for the company. Wedbush started coverage on Arvinas in a research report on Tuesday, September 24th. They set an “outperform” rating and a $38.00 price objective for the company. Finally, ValuEngine cut Arvinas from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $32.75.

A number of institutional investors and hedge funds have recently bought and sold shares of ARVN. BlackRock Inc. grew its holdings in Arvinas by 124.5% in the 2nd quarter. BlackRock Inc. now owns 1,038,838 shares of the company’s stock valued at $22,845,000 after buying an additional 576,137 shares during the period. Point72 Asset Management L.P. grew its holdings in Arvinas by 65.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 688,623 shares of the company’s stock valued at $15,143,000 after buying an additional 273,623 shares during the period. Bank of America Corp DE grew its holdings in Arvinas by 14,782.2% in the 2nd quarter. Bank of America Corp DE now owns 232,609 shares of the company’s stock valued at $5,116,000 after buying an additional 231,046 shares during the period. Nuveen Asset Management LLC purchased a new stake in Arvinas in the 2nd quarter valued at about $4,834,000. Finally, Vanguard Group Inc. grew its holdings in Arvinas by 33.0% in the 2nd quarter. Vanguard Group Inc. now owns 545,305 shares of the company’s stock valued at $11,991,000 after buying an additional 135,177 shares during the period. Institutional investors own 47.24% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

See Also: Inverted Yield Curve

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.